Silence Therapeutics plc (LON:SLN – Get Free Report)’s share price passed below its 200-day moving average during trading on Thursday . The stock has a 200-day moving average of GBX 535 ($6.80) and traded as low as GBX 512 ($6.51). Silence Therapeutics shares last traded at GBX 535 ($6.80), with a volume of 913,528 shares traded.
Silence Therapeutics Stock Down 0.9 %
The stock has a fifty day moving average of GBX 535 and a 200 day moving average of GBX 535. The firm has a market capitalization of £480.35 million and a P/E ratio of -11.01. The company has a debt-to-equity ratio of 0.80, a current ratio of 4.52 and a quick ratio of 4.36.
Silence Therapeutics Company Profile
Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development of novel ribonucleic acid (RNA) therapeutics in hematology, cardiovascular, and other rare and metabolic indications. The company's platform includes mRNAi GalNAc Oligonucleotide Discovery platform designed to accurately target specific disease-associated genes in the liver.
Further Reading
- Five stocks we like better than Silence Therapeutics
- How to Invest in Tech Stocks and Top Tech Stocks to Consider
- Darden Stock Up After Q4 Earnings Beat, Cautious FY25 Outlook
- How to Use Stock Screeners to Find Stocks
- Celsius Stock: Why Piper Sandler Forecasts a 50% Surge
- Industrial Products Stocks Investing
- Accenture’s Stock Earnings Reveal an AI-Powered Growth Strategy
Receive News & Ratings for Silence Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Silence Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.